Tracking SARS-CoV-2 variants

All viruses, including SARS-CoV-2, the virus that causes COVID-19, change over time. Most changes have little to no impact on the virus’s properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. 

In June 2020, the WHO Virus Evolution Working Group was established with a specific focus on SARS-CoV-2 variants, their phenotype and their impact on countermeasures. This later became the Technical Advisory Group on SARS-CoV-2 Virus Evolution. In late 2020, the emergence of variants that posed an increased risk to global public health prompted WHO to characterize some as variants of interest (VOIs) and variants of concern (VOCs) in order to prioritize global monitoring and research, and to inform and adjust the COVID-19 response. From May 2021 onwards, WHO began assigning simple, easy-to-say labels for key variants.

Considerable progress has been made in establishing and strengthening a global system to detect signals of potential VOIs or VOCs and rapidly assess the risk posed by SARS-CoV-2 variants to public health. More specifically, in 2024 WHO launched a WHO Coronavirus Network (CoViNet) to facilitate early and accurate detection of coronaviruses and variant tracking including coordinating risk evaluations. It remains critical that these systems are maintained, and data are shared, according to good principles and in a timely fashion, as SARS-CoV-2 continues to circulate at high levels around the world. While monitoring the circulation of SARS-CoV-2 globally, it also remains essential to monitor their spread in animal populations and chronically infected individuals, which are crucial aspects of the global strategy to reduce the occurrence of mutations that have negative public health implications. In March 2023, WHO updated its tracking system and working definitions for variants of concern, variants of interest and variants under monitoring. They can be found here. The previous working definitions can be found here.

 

Currently circulating variants of concern (VOCs) as of 15 March 2023

Currently circulating variants of interest (VOIs) (as of 9 February 2024)

 

Pango lineageNextstrain cladeGenetic featuresEarliest documented samplesDate of designation and risk assessments
XBB.1.523A

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1, with a breakpoint in S1. 

XBB.1 + S:F486P (similar Spike genetic profile as XBB.1.9.1)

Includes

XBB.1.5.70 (23G): XBB.1.5 + S:L455F and S:F456L


21-10-2022
11-01-2023





XBB.1.1623B

 

Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ.1 and BM.1.1.1

XBB.1 + S:E180V, S:K478R and S:F486P 
09-01-2023

17-04-2023

XBB.1.16 Initial Risk Assessment, 17 April 2023

XBB.1.16 Updated Risk Assessment, 05 June 2023

EG.5Not assigned

 

 

XBB.1.9.2 + S:F456L

Includes

EG.5.1 (23F): EG.5 + S:Q52H

HK.3 (23H): EG.5 + S:Q52H, S:L455F

HV.1: EG.5 + S:Q52H, S:F157L, S:L452R

 

17-02-2023

09-08-2023

EG.5 Initial Risk Evaluation, 09 August 2023

EG.5 Updated Risk Evaluation, 21 September 2023

EG.5 Updated Risk Evaluation, 21 November 2023

BA.2.86$23I

 

Mutations relative to BA.2

 

 

24-07-2023

21-11-2023

BA.2.86 Initial Risk Evaluation, 21 November 2023

 

JN.1

 

Not assigned

BA.2.86 + S:L455S

25-08-2023

18-12-2023

JN.1 Initial Risk Evaluation 18 December 2023

JN.1 Updated Risk Evaluation 9 February 2024

JN.1 Updated Risk Evaluation 15 April 2024

 

$ Excludes BA.2.86 sublineages listed here as VOIs.

 

Currently circulating variants under monitoring (VUMs) (as of 10 April 2024)

 

Networks

Publications

All →
WHO guiding principles for pathogen genome data sharing

WHO encourages the sharing of pathogen genome data to protect global public health. Sharing of pathogen genome data is critical for preventing, detecting,...

Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August 2021

This document aims to describe a minimum set of surveillance activities recommended at the national level to detect and monitor the relative prevalence...

SARS-CoV-2 genomic sequencing for public health goals: Interim guidance, 8 January 2021

The growing understanding of how sequence information can contribute to improved public health is driving global investments in sequencing facilities and...

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health

Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing...